Promising pill may stall brain tumors in HER2+ breast cancer
NCT ID NCT05041842
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug tucatinib to standard treatments (pertuzumab and trastuzumab) can help people with HER2-positive metastatic breast cancer whose cancer has progressed in the brain after local therapy. About 53 participants will receive tucatinib pills twice daily along with their regular infusions. The main goal is to see how many are alive without further cancer growth six months later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucatinib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could offer a new treatment option for people with HER2+ breast cancer that has spread to the brain, potentially delaying further progression.
What could go wrong
This is a small, early-phase study (53 participants) without a comparison group, so results may not be definitive. Side effects of tucatinib can include diarrhea, nausea, and liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER WITH A ISOLATED BRAIN PROGRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi
Plérin, France
-
Centre Antoine Lacassagne
Nice, France
-
Centre Francois Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Universitaire de Tours
Tours, France
-
Centre Leon Berard
Lyon, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Gustave Roussy
Villejuif, France
-
Hôpital privé Jean Mermoz
Lyon, France
-
Institut Bergonié
Bordeaux, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Jean Godinot
Reims, France
-
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France
-
Institut du cancer de Montpellier
Montpellier, 34090, France